Dayvigo Compounding Legal Status: What Patients and Prescribers Need to Know

Lemborexant, marketed as Dayvigo by Eisai Inc., is a dual orexin receptor antagonist (DORA) that received FDA approval on December 20, 2019 (NDA 211775) for treating insomnia in adults. The medication is available in 5 mg and 10 mg immediate-release tablet formulations and carries Schedule IV classification under the Controlled Substances Act.

Lemborexant cannot currently be compounded legally by a 503A pharmacy or a 503B outsourcing facility. Two independent facts drive that conclusion: lemborexant is a Schedule IV controlled substance, and as of this writing it does not appear on the FDA drug shortage list, which forecloses the shortage-based compounding exception that allowed compounded semaglutide and tirzepatide to circulate. Compounding status can change if either fact changes, so prescribers and patients should treat "not compoundable" as a current status rather than a permanent one. (FDA compounding policy: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies; FDA drug shortage database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm)

Why compounding Dayvigo is not legal right now

The controlled-substance barrier

The Drug Quality and Security Act of 2013 established Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, permitting compounding of select FDA-approved medications within specific parameters. Compounded formulations must not constitute an "essentially a copy" version of an approved commercial product, with heightened FDA oversight applied to controlled substances. Since the DEA designates lemborexant as Schedule IV (grouped with zolpidem and most benzodiazepines), any pharmacy compounding lemborexant must concurrently comply with FDA compounding regulations and DEA requirements for Schedule IV substance handling, registration, and recordkeeping. To date, no publicly registered 503B outsourcing facility includes lemborexant among its compounded offerings. (https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies)

The shortage pathway does not apply

The compounding activity that became visible with semaglutide and tirzepatide depended on those drugs appearing on the FDA drug shortage list, which opened a temporary 503B exception. Dayvigo does not currently appear on that list, so the same pathway is not open for lemborexant. This status is date-sensitive: shortage listings change, and readers should check the FDA database directly before assuming it is unchanged. (https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm)

What a telehealth prescriber should tell a patient

Any platform advertising "compounded lemborexant" or a "generic Dayvigo" outside of an FDA-approved generic product is describing something that is not legally available under current federal rules. Prescribers have a reasonable duty to correct that impression rather than let a patient believe compounded lemborexant is a legitimate lower-cost option.

Decision framework: is a "compounded Dayvigo" or "generic lemborexant" offer legitimate?

Use this sequence when a patient asks about a compounding pharmacy, a telehealth ad, or an online offer claiming to sell lemborexant outside a standard pharmacy dispensing of brand Dayvigo.

Step 1: Confirm what is actually being sold.

• If it is brand-name Dayvigo dispensed from a licensed retail or mail-order pharmacy with a valid prescription, this is standard dispensing, not compounding, and is legal.
• If it is described as "compounded," "custom-dosed," or a "research-grade" version of lemborexant, move to Step 2.

Step 2: Check the two gating facts.

• Is lemborexant currently listed on the FDA drug shortage database? If yes, a narrow compounding exception may exist and should be evaluated case by case with the pharmacy's 503A/503B registration status. If no (the current status), compounding is not a legal option regardless of price or convenience claims.
• Is the seller a DEA-registered facility with documented Schedule IV handling authority? If the seller cannot produce this, treat the offer as non-compliant.

Step 3: Apply the exception test. A legal compounded preparation must be tied to a documented patient-specific medical need (for example, a diagnosed allergy to an excipient in the FDA-approved tablet) that cannot be met by the commercial product, not simply lower price or convenience. Generalized marketing of compounded lemborexant to anyone who wants a discount fails this test.

Step 4: If the offer fails Steps 2 or 3, do not proceed.

• Redirect the patient to brand Dayvigo through a licensed pharmacy, to Eisai's patient assistance program if cost is the barrier, or to an alternative FDA-approved insomnia therapy discussed with their prescriber.
• Report the offer to FDA MedWatch (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) and to the relevant state board of pharmacy.

Step 5: Reassess only if the underlying facts change. Re-run this framework if lemborexant is added to the FDA shortage list, if a new FDA generic is approved, or if FDA issues new guidance specific to Schedule IV compounding. None of these conditions is currently met.

FDA approval history

FDA approved Dayvigo on December 20, 2019, under NDA 211775, covering 5 mg and 10 mg immediate-release tablets for insomnia disorder in adults. Eisai's application relied on a phase 2 dose-finding study and two phase 3 trials, SUNRISE-1 and SUNRISE-2. FDA required post-marketing commitments, including a human abuse potential (HAP) study and a pediatric study under the Pediatric Research Equity Act. As of this writing, the adult indication remains the only FDA-approved use; a pediatric indication has not been established here and should be verified against the current label before assuming otherwise.

What SUNRISE-1 and SUNRISE-2 showed

SUNRISE-1 was a phase 3, randomized, double-blind, placebo-controlled trial in adults with insomnia disorder comparing lemborexant 5 mg and 10 mg against placebo over roughly a year, using diary-based measures of sleep onset and sleep efficiency. SUNRISE-2 added zolpidem extended-release as an active comparator over six months. Across both trials, lemborexant at both doses outperformed placebo on subjective sleep-onset measures, and the effect did not appear to diminish sharply over the trial period.

The specific numeric effect sizes cited in earlier drafts of this article (exact minutes of sleep-onset reduction, specific p-values, and specific fall-rate percentages) are not confirmed against a verified primary source in this review and should not be treated as settled facts until checked against the published SUNRISE-1 and SUNRISE-2 papers and the FDA label. Readers who need exact figures for clinical decision-making should pull the primary trial publications directly rather than relying on this summary.

What the Dayvigo label addresses

The FDA-approved prescribing information for lemborexant is the authoritative source for dosing and warnings. In general terms, consistent with that labeling:

• The recommended starting dose is 5 mg taken once nightly, immediately before bed, with sufficient time remaining before the planned wake time; the dose may be increased to 10 mg based on response and tolerability, and 10 mg is the maximum approved dose. Readers should confirm the exact label language directly rather than rely on a paraphrase for clinical dosing decisions, and this article does not provide individualized dosing advice.
• A boxed warning covers complex sleep behaviors, including sleepwalking and sleep-related activities performed without full awareness, some of which have led to serious injury. This warning is shared across approved hypnotics.
• Additional warnings address next-day impairment in alertness and coordination, potential worsening of depression or suicidal ideation in patients with underlying psychiatric conditions, and sleep paralysis or hypnagogic hallucinations.
• Lemborexant is metabolized by CYP3A4. Co-administration with strong CYP3A4 inhibitors is contraindicated because of the risk of markedly increased drug exposure and sedation; moderate CYP3A4 inhibitors generally require a lower dose. Prescribers managing patients on antifungals, certain antibiotics, or antiretrovirals should check the current label's interaction table rather than assume any specific drug is safe to combine.
• Narcolepsy is a contraindication, because blocking orexin signaling in an already orexin-deficient patient could plausibly worsen cataplexy. Severe hepatic impairment is also a contraindication due to reduced clearance.

Safety signals that require ongoing monitoring, not one-time reassurance

Abuse potential and Schedule IV status

Because lemborexant is Schedule IV, FDA required a human abuse potential study as part of approval. In general, such studies compare a candidate drug's subjective "drug liking" profile against placebo and against a known abuse-potential benchmark. Whether lemborexant's specific abuse-liability findings were "substantially lower" than a comparator such as triazolam, as sometimes reported in secondary sources, is a precise claim that requires verification against the actual post-marketing study before being restated as fact. What is established is the regulatory outcome: FDA and DEA placed lemborexant in Schedule IV, the same category as zolpidem and most benzodiazepines, rather than a less restrictive schedule.

Next-morning impairment and falls

The label addresses next-day impairment in alertness and motor coordination, and clinical trial safety data reportedly showed a higher rate of fall-related adverse events in older adults taking the 10 mg dose compared with placebo. The exact percentages associated with this finding are not confirmed against a verified primary source here and should be checked against the SUNRISE-1 publication and the current label before being used in patient counseling. What is established without needing exact figures: prescribers should use caution when prescribing any orexin receptor antagonist to patients 65 and older, consistent with general geriatric prescribing caution applied to sedative-hypnotics as a class.

Pregnancy and special populations

The label recommends avoiding lemborexant during pregnancy based on animal reproduction data showing fetal harm at clinically relevant exposures; adequate and well-controlled human pregnancy trials are not available. This is a labeling caution, not a demonstrated human teratogenic effect, and patients who are pregnant or planning pregnancy should discuss alternatives with their prescriber rather than assume the animal data translate directly to human risk.

Orexin receptor antagonists compared with other insomnia drug classes

Orexin peptides promote wakefulness by binding OX1R and OX2R receptors in arousal-related brain regions. Lemborexant blocks both receptors, reducing the wakefulness signal rather than directly amplifying inhibitory (GABA-A) signaling the way zolpidem and benzodiazepines do. This mechanistic difference is well established. Whether it produces a meaningfully different abuse or dependence profile in practice is plausible based on mechanism and supported in part by the Schedule IV classification decision, but it is not the same as an established lower-risk claim, since lemborexant still carries Schedule IV status and the same boxed warning for complex sleep behaviors as other hypnotics.

Suvorexant (Belsomra, Merck), approved in 2014, was the first DORA and is also Schedule IV. Head-to-head comparisons between suvorexant and lemborexant exist in the literature, but this review did not verify a specific comparative trial against a confirmed primary source, so no exact superiority claim is made here. Prescribers comparing the two agents should consult the current labels and a verified head-to-head publication rather than rely on a secondary summary.

The American Academy of Sleep Medicine's guideline work on chronic insomnia in adults generally favors cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, ahead of any pharmacologic agent, with medication reserved for patients who do not have access to or do not respond adequately to CBT-I. Readers should consult the current AASM guideline directly for the specific recommendation grading and comparative statements about DORAs versus other drug classes, since the exact wording and grade of any preference statement is not verified against a confirmed source here.

Generic lemborexant and cost

As of this writing, an FDA-approved generic lemborexant has not been identified in the sources reviewed for this article. Patent status, Paragraph IV challenge timelines, and any resulting 30-month stay dates are the kind of volatile, litigation-dependent facts that change without notice; specific years or dates for expected generic entry should not be treated as reliable unless confirmed against the FDA Orange Book and current litigation filings on the date the reader checks.

Cost figures such as list price, co-pay assistance amounts, and the share of Medicare Part D plans covering lemborexant on a given tier are similarly volatile and were not independently verified for this review. Patients concerned about cost should contact Eisai's patient support program directly and check their specific plan's current formulary rather than rely on a fixed number quoted here.

Could Dayvigo ever be legally compounded?

Three circumstances could change the current answer, though none has occurred as of this writing:

1. If Eisai discontinued Dayvigo commercially and FDA added it to a discontinued-drug list, compounding rules for discontinued drugs would apply differently, though Schedule IV status would remain a separate obstacle.
2. A change to the Controlled Substances Act creating a different category for lower-abuse-potential orexin antagonists could alter the calculus. No such legislation is known to be pending.
3. FDA could issue guidance specifically permitting 503B compounding of Schedule IV substances under conditions similar to the shortage pathway. FDA has not issued such guidance as of this writing.

Until one of these changes occurs, compounding lemborexant remains outside current federal law. Prescribers who encounter marketing claiming otherwise should report it through FDA MedWatch (https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program) and to their state board of pharmacy.

Prescriber checklist before starting Dayvigo

• Confirm a documented insomnia disorder diagnosis with onset, duration, and functional impact noted.
• Confirm CBT-I has been discussed as a first-line option.
• Rule out narcolepsy and severe hepatic impairment.
• Complete a full medication reconciliation with specific attention to CYP3A4 inhibitors.
• Confirm the patient is not pregnant and discuss contraception if of childbearing potential.
• Counsel specifically on complex sleep behaviors and instruct the patient to stop the drug and contact the prescriber if any such event occurs.
• Complete a controlled substance agreement and PDMP check consistent with state law.
• Schedule a follow-up appointment to reassess ongoing need for therapy, consistent with the label's recommendation for periodic reassessment.
• Confirm with the patient that no compounded or "generic" lemborexant exists outside a licensed pharmacy dispensing FDA-approved brand product, using the decision framework above if a compounding offer surfaces.

What this article cannot tell you

This article summarizes regulatory status and label-level safety information. It cannot tell an individual patient what dose is appropriate, whether Dayvigo is the right choice compared with another insomnia treatment, or how to interpret a specific abnormal lab or symptom. Patients experiencing a suspected adverse reaction, including any episode of activity performed without full awareness while on the drug, should contact their prescriber promptly and seek urgent care for any injury.